NCT00887809View on ClinicalTrials.gov

Gemcitabine and Docetaxel With Bevacizumab in Selected Sarcoma Subtypes

PHASE2CompletedINTERVENTIONAL

Enrollment

47

Participants

Timeline

Start Date

April 30, 2009

Primary Completion Date

October 31, 2014

Study Completion Date

November 30, 2014

Conditions

SarcomaLeiomyosarcomaMalignant FibrousHistiocytomaAngiosarcoma

Interventions

DRUG

gemcitabine

DRUG

docetaxel

DRUG

bevacizumab

Trial Locations (1)

10065

Memorial Sloan-Kettering Cancer Center, New York

Sponsors

Collaborators (1)

Genentech, Inc.

All Listed Sponsors

collaborator

Genentech, Inc.

INDUSTRY

lead

Memorial Sloan Kettering Cancer Center

OTHER

NCT00887809 - Gemcitabine and Docetaxel With Bevacizumab in Selected Sarcoma Subtypes | Biotech Hunter | Biotech Hunter